文献速递浆细胞疾病

线粒体丙酮酸载体复合物增强多发性骨髓瘤中蛋白酶体抑制剂的疗效

The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma.
PubMed 文献 · Blood Adv · 2023-01-01

该研究通过全基因组CRISPR筛选,在两种人骨髓瘤细胞系中发现线粒体丙酮酸载体(MPC)复合物亚基MPC1是硼替佐米应答的共性调控因子;CRISPR缺失或药理抑制MPC可增强硼替佐米/卡非佐米诱导的骨髓瘤细胞死亡,并伴随蛋白酶体活性降低;晚期骨髓瘤中丙酮酸代谢调控因子RNA表达改变且与不良预后相关。

要点

  • 全基因组CRISPR筛选鉴定MPC1为两种骨髓瘤细胞系中硼替佐米应答的共性调控因子。
  • CRISPR缺失或药理抑制MPC复合物增强硼替佐米/卡非佐米诱导的骨髓瘤细胞死亡。
  • 靶向MPC复合物损害骨髓瘤细胞生物能量能力并降低蛋白酶体活性。

核心结论

  • MPC复合物对骨髓瘤细胞存活及其对蛋白酶体抑制剂的应答具有重要作用。
  • 线粒体丙酮酸代谢是治疗骨髓瘤的潜在靶点,也是提高蛋白酶体抑制剂临床疗效的策略。

研究设计与样本

  • 研究采用全基因组CRISPR筛选,在两种不同人骨髓瘤细胞系中体外鉴定硼替佐米应答调控因子。

主要发现

  • CRISPR缺失或药理抑制MPC复合物增强硼替佐米/卡非佐米诱导的骨髓瘤细胞死亡,对细胞周期进程影响极小。
  • 靶向MPC复合物损害骨髓瘤细胞生物能量能力,伴随蛋白酶体活性降低,从而在体外加剧硼替佐米诱导的细胞毒性。
  • 晚期骨髓瘤中若干丙酮酸代谢调控因子的RNA表达水平改变,且与患者不良预后相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a hematological malignancy that emerges from antibody-producing plasma B cells. Proteasome inhibitors, including the US Food and Drug Administration-approved bortezomib (BTZ) and carfilzomib (CFZ), are frequently used for the treatment of patients with MM. Nevertheless, a significant proportion of patients with MM are refractory or develop resistance to this class of inhibitors, which represents a significant challenge in the clinic. Thus, identifying factors that determine the potency of proteasome inhibitors in MM is of paramount importance to bolster their efficacy in the clinic. Using genome-wide CRISPR-based screening, we identified a subunit of the mitochondrial pyruvate carrier (MPC) complex, MPC1, as a common modulator of BTZ response in 2 distinct human MM cell lines in vitro. We noticed that CRISPR-mediated deletion or pharmacological inhibition of the MPC complex enhanced BTZ/CFZ-induced MM cell death with minimal impact on cell cycle progression. In fact, targeting the MPC complex compromised the bioenergetic capacity of MM cells, which is accompanied by reduced proteasomal activity, thereby exacerbating BTZ-induced cytotoxicity in vitro. Importantly, we observed that the RNA expression levels of several regulators of pyruvate metabolism were altered in advanced stages of MM for which they correlated with poor patient prognosis. Collectively, this study highlights the importance of the MPC complex for the survival of MM cells and their responses to proteasome inhibitors. These findings establish mitochondrial pyruvate metabolism as a potential target for the treatment of MM and an unappreciated strategy to increase the efficacy of proteasome inhibitors in the clinic.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Findlay S, Nair R, Merrill RA, et al. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma. Blood Adv. 2023. PMID: 36920785. doi:10.1182/bloodadvances.2022008345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。